Cost-effectiveness analysis of genotype-guided optimization of major depression treatment in Qatar.

ABSTRACT:

Background

Pharmacogenetic testing improves the efficacy and safety of antidepressant pharmacotherapy for moderate-severe major depressive disorder by identifying genetic variations that influence medication metabolism, and adjusting treatment regimens accordingly. This study aims to assess the cost-effectiveness of implementing a pharmacogenetic testing approach to guide the prescription of antidepressants.

Methods

From the public hospital perspective, we developed a two-stage decision tree diagram of a short-term 6-week follow up, and a lifetime Markov model with 3-month cycles. The analysis compared the current standard of care with the alternative strategy of Pharmacogenetic-guided (multi-gene panel) testing in adult patients with moderate-severe major depressive disorde

SUBMITTER: Abushanab D 

PROVIDER: S-EPMC11514395 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature